The DOI matches its Crossref record; 32 of the 44 references it cites were found in a registry or an index, and 12 are not checked yet; none of the 37 sources its claims cite is checked for support yet.
p53 Deficiency Rescues the Adverse Effects of Telomere Loss and Cooperates with Telomere Dysfunction to Accelerate Carcinogenesis
Open accessAbstract
Maintenance of telomere length and function is critical for the efficient proliferation of eukaryotic cells. Here, we examine the interactions between telomere dysfunction and p53 in cells and organs of telomerase-deficient mice. Coincident with severe telomere shortening and associated genomic instability, p53 is activated, leading to growth arrest and/or apoptosis. Deletion of p53 significantly attenuated the adverse cellular and organismal effects of telomere dysfunction, but only during the earliest stages of genetic crisis. Correspondingly, the loss of telomere function and p53 deficiency cooperated to initiate the transformation process. Together, these studies establish a key role for p53 in the cellular response to telomere dysfunction in both normal and neoplastic cells, question the significance of crisis as a tumor suppressor mechanism, and identify a biologically relevant stage of advanced crisis, termed genetic catastrophe.
Checked 2026-10-06 · 12 references not checked yet
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In telomerase-deficient (mTR−/−) mice, critically short telomeres activate p53, and deleting p53 rescues the resulting apoptosis and cell-cycle arrest — but only during early "crisis." Loss of telomere function and p53 deficiency cooperate to initiate transformation, while telomerase reconstitution mainly benefits later stages of tumorigenesis.
Key findings
- Critical telomere shortening activates p53: p53 protein was detectable in G6 mTR−/− testis but not in mTR+/+ or G6 mTR−/− p53−/− littermates; >80% of G4 and G6 MEFs stained positive for p53 at passage 6 versus 21% of mTR+/+ MEFs. p21CIP1/WAF1 rose 3- to 4-fold in G6 versus G2 mTR−/− p53+/+ MEFs, and p53-dependent CAT reporter activity increased ~2-fold.
- p53 loss rescued telomere-dysfunction phenotypes early but not late: 15% of G4–G6 mTR−/− mice (86/565) were p53−/− versus 26% of G7–G8 mice (24/91) (p = 0.015); all G5 mTR−/− p53−/− testes had normal histology, but 3 of 7 G6 and all five G7–G8 samples showed germ cell depletion. G6 mTR−/− p53−/− MEFs showed a 3-fold increase in chromosome fusions (1.65, SD 2.59 vs 0.42, SD 0.71 per metaphase; p = 0.012), with no change in telomere length (75% reduction regardless of p53 status).
- Telomere dysfunction cooperated with p53 deficiency to initiate transformation: adding mTR suppressed Myc/RAS focus formation in G6 mTR−/− p53−/− MEFs, but mTR-transfected foci had higher subcloning efficiency (23/26, 89%) than vector foci (19/32, 59%; p = 0.018). Tumor formation in SCID mice was similar between groups.
- The authors propose dividing crisis into p53-dependent "early crisis" and p53-independent "genetic catastrophe," questioning crisis as a tumor suppressor mechanism.
Methods
- Mouse genetics: mTR+/− mice crossed with p53+/− mice to generate successive generations (G1–G8) of mTR−/− animals with p53+/+, +/−, and −/− genotypes in a mixed WW6/C57BL/6 background; p53 status maintained heterozygous during matings.
- Cellular/organ assays: immunoblotting and immunohistochemistry for p53 and p21, pG13CAT reporter assays, testis histology with TUNEL, BrdU/propidium iodide FACS cell-cycle profiles, flow FISH telomere length, and metaphase spreads for chromosome fusions.
- Transformation assays: Myc/RAS cotransfection of early-passage MEFs with empty vector or an mTR genomic fragment, scoring focus formation, subcloning efficiency, and tumor formation after subcutaneous injection into SCID mice.
Limitations
- Stated: the mechanisms by which tumorigenic potential is maintained in late stages of tumorigenesis despite telomere dysfunction "remain to be determined"; whether loss of TRF2 binding, short telomeres, or fusion-bridge-breakage cycles mediate the p53 induction described also remains undetermined.
- Evident from the text: the G7–G8 genotype comparison rests on small numbers (24 of 91 mice), and all mice are in a mixed genetic background, which the authors note required cousin mating to avoid substrains.
- Evident from the text: the transformation data are from cultured MEFs and SCID xenografts, and tumor weights/efficiency between mTR and vector lines were not significantly different, so the in vivo relevance of the initiation advantage is inferred rather than directly demonstrated.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
40 Own interpretation · 39 Own result · 22 Not checked yet · 6 Own method · 4 No basis given
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Correspondingly, the loss of telomere function and p53 deficiency cooperated to initiate the transformation process.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Coincident with severe telomere shortening and associated genomic instability, p53 is activated, leading to growth arrest and/or apoptosis.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This activity was strictly dependent upon p53, since p53−/− and G6 mTR−/− p53−/− MEF cultures showed only background levels of CAT activity.”
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found that p53 mediates the adverse effects of critically shortened telomeres.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As shown in Figure 3A, DNA content analyses of G6 mTR−/− p53+/+ MEFs revealed a profile consistent with a biphasic block as evidenced by marked accumulation of cells in G1 and G2/M phases.”
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Indeed, analysis of metaphase spreads derived from G6 mTR−/− p53+/+ MEFs showed a rate of 0.42 (SD 0.71) chromosomal fusions per metaphase, a rate consistent with previous studies (Figure 3D) (Blasco et al. 1997; Greenberg et al. 1999; Rudolph et al. 1999”
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, p53-independent cell death becomes a more consistent feature in G7 and G8, since all of the five G7–G8 mTR−/− p53−/− testis samples showed significant germ cell depletion microscopically (Figure 2D).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, a relative increase in p53−/− mice was evident in G7 and G8 mTR−/− background (24% and 38%, respectively).”
plaincorrelationaln = 91 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Gross testis size was consistently rescued to near normal in G6 mTR−/− p53−/− mice compared to G6 mTR−/− p53+/+ littermates (see Figure 2A for representative comparison).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, loss of telomere function and p53 deficiency can cooperate to enhance transformation.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 36
- The quote only partly states this claim. 1
- Probably not a substantial claim. 16
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Deletion of p53 significantly attenuated the adverse cellular and organismal effects of telomere dysfunction, but only during the earliest stages of genetic crisis.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast, mTR+/+ p53+/+ MEF cultures demonstrated 35% of cells in S phase and only 13% in G2/M.”
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In mTR+/+ testis, p53 status did not affect testicular volume or significantly alter the cytoarchitecture of seminiferous tubules (Figure 2A and Figure 2B).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Whereas only 21% of the mTR+/+ MEFs at passage 6 stained positive for p53, more than 80% of MEFs derived from G4 and G6 exhibited strong immunoreactivity to p53 (Figure 1B, compare [a] with [b] and [c]).”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In male germ cells and lymphocytes, telomere loss elicits a strong apoptotic response, whereas MEFs experience a potent biphasic cell cycle block.”
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Whereas all G5 mTR−/− p53−/− testes exhibited normal histology, 3 of 7 G6 mTR−/− p53−/− samples still showed varying degrees of pathology (Table 1).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Accordingly, BrdU incorporation assay showed that 36% of the G6 mTR−/− p53+/+ cells were in G1 phase, 3% were in S phase, and 40% were in G2/M (Figure 3A, top panel).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Immunoprecipitation and Western blot analysis readily detected p53 in lysates from G6 mTR−/− testis, but not in lysates derived from age-matched mTR+/+ testis or from G6 mTR−/− p53−/− littermate controls (Figure 1A).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“This induction of p53 coincides with the dramatic increase in apoptosis (as assessed by TUNEL) and decreased cellularity in the G6 mTR−/− testis (Lee et al. 1998”
What the sources say
- Not checked yetcites Lee et al. 1998 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Significantly, loss of p53 rescues the cell cycle arrest in MEFs and the apoptotic elimination of male germ cells.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“loss of p53 abrogated this block.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Significantly, 15% of the G4–G6 mTR−/− mice (86 out of 565 mice) were p53−/− compared to 26% of the G7–G8 mTR−/− mice (24 of 91 mice) (p = 0.015 by Fisher’s two-sided t test) (Figure 1E).”
plaincorrelationaln = 565 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“By comparison, G6 mTR−/− p53−/− MEFs exhibited 1.65 (SD 2.59) fusions per metaphase, a 3-fold increase (p = 0.012).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the case of MEFs, this arrest occurs in concert with the stabilization and activation of the p53 protein, evident in p53-dependent reporter assays and activation of p21CIP1/WAF1.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similar differences were observed in low-density seeding experiments (data not shown).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In human cells, a critical telomere length is eventually reached that induces cellular senescence, thus limiting the replicative capacity of cultured cells at the Hayflick limit (Hayflick and Moorhead 1961”
What the sources say
- Not checked yetcites Hayflick and Moorhead 1961 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
In the paper
“In primary cells deficient for Rb and p53, continued cellular growth beyond the Hayflick limit results in severe telomere shortening, marked genetic instability, and massive cell death—a period referred to as crisis (Counter et al. 1992”
What the sources say
- Not checked yetcites Counter et al. 1992 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Ectopically expressed hTERT maintains telomere length and allows unlimited growth (Bodnar et al. 1998; Counter et al. 1998; Vaziri and Benchimol 1998”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The notion that telomere function may indeed be required for immortalization is supported by the frequent activation of telomerase or ALT in human cancers (Kim et al. 1994; Bryan et al. 1995”
What the sources say
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The telomere signal that activates this senescent program operates through the RB and p53 pathways, since cell division beyond the Hayflick limit can occur after antisense neutralization (Hara et al. 1991”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“Telomerase is comprised of essential catalytic (telomerase reverse transcriptase [TERT]) and RNA components (telomerase RNA [TR]) (reviewed in Greider 1998”
What the sources say
- Not checked yetcites Greider 1998 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Strikingly, as mTR−/− mice advance with age and generation, an increase in cancer incidence is observed presumably due to increased genetic instability caused by telomere shortening, repeated chromosomal fusion-bridge-breakage cycles, and chromosomal loss (Rudolph et al. 1999”
What the sources say
- Not checked yetcites Rudolph et al. 1999 source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Due to the very long telomeres of Mus musculus, critical reduction in telomere length and chromosomal instability is only seen following extensive passage of mTR−/− cells (Niida et al. 1998”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The RNA subunit provides the template for telomere repeat synthesis (Greider and Blackburn 1989; Yu et al. 1990”
What the sources say
- Not checked yetcites Greider and Blackburn 1989
- Not checked yetcites Yu et al. 1990
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“although immortalization of some epithelial cells requires not only TERT expression but also compromise of the RB pathway (Kiyono et al. 1998”
What the sources say
- Not checked yetcites Kiyono et al. 1998 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although loss of telomere and p53 function facilitates initiation of transformation, the reconstitution of telomerase activity greatly improved the capacity of transformed foci to yield immortal cultures.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Because G2 mTR−/− and G6 mTR−/− MEFs both lack telomerase activity, we conclude that telomere shortening or associated chromosome fusions and breakage rather than telomerase deficiency per se signals to p53 and accounts for p21CIP1/WAF1 induction.”
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, the rampant genetic instability of the G7 and G8 mTR−/− p53−/− cells is associated with loss of cell viability despite p53 deficiency, implying that advanced genomic catastrophe gives way to a p53-independent process.”
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These results indicate that telomere dyfunction acts synergistically with p53 deficiency to initiate malignant transformation, presumably by enhancing genetic instability.”
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Continued proliferation in the absence of the p53 checkpoint may lead to an increased loss of telomere sequences and therefore account for the increased frequency of chromosome fusions.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For these matings, the p53 status was maintained in the heterozygous state to avoid potential broad genomic effects arising from p53 deficiency.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The ability of exogenous telomerase to reduce focus formation in p53 null cells with short dysfunctional telomeres suggests that genetic instability associated with telomere loss can serve as an engine driving initiation of transformation, but only in the absence of functional p53 (Figure 5).”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Focus formation reflects the earliest stages of oncogenic transformation.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Early crisis accounts for efficient germ cell depletion in G6 mTR−/− p53+/+, whereas the altered histology of G7 and G8 mTR−/− p53−/− testis provides experimental support for late crisis.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Together, these data indicate that p53 deficiency restores neither telomere length nor function in the telomerase-deficient mouse.”
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“This mating scheme also produced p53+/+ and p53−/− littermate controls for each mTR−/− generation.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
None of the sources cited for this claim have been checked yet.
In the paper
“Telomere shortening in mTR−/− mice results in loss of telomere function and chromosome end-to-end fusion (Blasco et al. 1997; Rudolph et al. 1999”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The observation that mTR expression facilitates subcloning efficiency of Myc/RAS-transformed late-generation mTR−/− cells supports the importance of telomere maintenance mechanisms during later stages of carcinogenesis.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Induction of double strand breaks in DNA by ionizing radiation or genotoxic chemotherapy leads to the rapid stabilization of p53 through phosphorylation of its N terminus (Shieh et al. 1997; Siliciano et al. 1997”
What the sources say
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Together with previous work, our data indicated that, first, during the early stages of tumorigenesis, cells suffer telomere shortening, and second, that telomerase activation is advantageous primarily in later stages of tumorigenesis.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: Many human tumors that are telomerase positive still have short telomeres.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cells with short telomeres and intact p53-mediated DNA damage responses may be more efficiently “culled” from the population (via apoptosis or arrest); therefore, p53 null cells may accumulate more end-to-end fusions than their p53+/+ counterparts.”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Once both telomere function and p53 have been impaired, the fate of the cell is unpredictable and depends on other stochastic genetic changes.”
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“This stabilization results in either cell cycle arrest via transcriptional induction of the p21CIP1/WAF1 CDK inhibitor or apoptosis (reviewed in Levine 1997”
What the sources say
- Not checked yetcites Levine 1997 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Loss of p53 can circumvent this checkpoint, leading eventually to p53-independent apoptosis, perhaps as a consequence of uncontrolled chromosome fusion-bridge-breakage cycles and progressive genomic instability.”
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, both the apoptotic response and cell cycle arrest induced by telomere dysfunction are mediated by p53.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For telomere length determination of MEFs, littermate MEF cultures were assayed simultaneously to reduce experimental variability.”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“At least two independent determinations of the same cultures were performed.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Day to day variations in the linearity of the flow cytometer were controlled by the use of FITC-labeled fluorescence beads (Flow Cytometry Standards Corporation).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Three independent age-matched sets of animals were used.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In mTR−/− INK4a−/− mice, it is likely that telomere dysfunction activates p53 via a DNA damage signaling pathway and results in growth arrest or apoptosis, limiting the efficiency of carcinogenesis”
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
The signals and pathways mediating the cellular responses associated with telomere dysfunction have yet to be defined in mammalian cells.
“The signals and pathways mediating these cellular responses associated with telomere dysfunction have yet to be defined in mammalian cells.”
The paper relies on this without support.
The RAD9 and MEC1 DNA damage response pathways in yeast are similar to the p53 checkpoint in mammalian cells.
“The RAD9 and MEC1 DNA damage response pathways in yeast are thought to be similar to the p53 checkpoint in mammalian cells.”
The paper relies on this without support.
The mTR−/− mouse is a valid model for studying the consequences of telomere loss in vivo.
“The mTR−/− mouse serves as a model to study the consequences of telomere loss in vivo.”
The paper relies on this without support.
Focus formation reflects the earliest stages of oncogenic transformation.
“Focus formation is thought to reflect the earliest stages of oncogenic transformation.”
The paper relies on this without support.
Human cells require inactivation of Rb and/or p53 to bypass the major checkpoint that limits replicative lifespan: cellular senescence.
“Human cells require inactivation of Rb and/or p53 to bypass the major checkpoint that limits replicative lifespan: cellular senescence.”
The paper relies on this without support.
Rb/p53 inactivation allows continued cell division beyond senescence, progressive telomere shortening, and entry into crisis, from which only rare survivors emerge.
“Rb/p53 inactivation allows continued cell division beyond senescence, progressive telomere shortening, and entry into crisis, from which only rare survivors will emerge.”
The paper relies on this without support.
Many human tumors that are telomerase positive still have short telomeres.
“The fact that many human tumors that are telomerase positive still have short telomeres supports the idea that telomerase activation occurs late in tumorigenesis.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although enabling cellular growth and survival and masking degenerative phenotypes, these mTerc -/ -p53 mutant mice experience a dramatic increase in cancer incidence, shift in tumor spectrum toward epithelial cancers, and accumulation of marked chromosomal aberrations targeting cancerrelevant loci for amplification and deletion (4-6).”
From Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse (2007) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Specifically, p53 deficiency results in nearcomplete rescue of adverse cellular consequences associated with telomere dysfunction, including cellular growth arrest and apoptosis, progressive organ system atrophy, and physiological compromise.”
From Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse (2007) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Telomere dysfunction appears to engage the p53-dependent double-stranded break DNA damage pathway.”
From Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse (2007) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When the p53 checkpoint is compromised, unchecked genomic instability caused by telomere dysfunction accelerates tumorigenesis as seen in late-generation mTerc -/ -p53 mutant mice (4, 5).”
From Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse (2007) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“recent reports of the effect of the mTR deletion in different genetic backgrounds (17, 18) suggest that the role of telomerase in cancer development could be highly context dependent (19).”
From Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death (1999) · cites this paper as [18]
In the citing paper
“By contrast, p53 inactivation alone is sufficient to avoid telomere-induced senescence and apoptosis in mice49,50.”
From Telomeres in cancer: tumour suppression and genome instability (2017) · cites this paper as [49]
In the citing paper
“In the absence of telomerase, continued cell division results in telomere shortening, loss of ‘capping’ function, and p53 activation12-15.”
From Telomere dysfunction induces metabolic and mitochondrial compromise (2011) · cites this paper as [15]
In the citing paper
“p53 deficiency markedly attenuates the degenerative phenotypes associated with telomere dysfunction, whereas constitutively activated p53 accelerates ageing phenotypes15-18.”
From Telomere dysfunction induces metabolic and mitochondrial compromise (2011) · cites this paper as [15]
In the citing paper
“Critically short telomeres induce cellular and tissue defects through checkpoint signaling pathways that converge on the p53 tumor suppressor protein, a well-known cellular stress sensor that enforces cell cycle arrest or cell death in response to diverse stimuli including activated oncogenes, DNA damage and hypoxia (69)”
From Telomeres and telomerase in cancer (2010) · cites this paper as [69]
In the citing paper
“The downstream effector pathways of telomere-induced senescence are largely p53-dependent96, but there may be involvement of the retinoblastoma protein (RB) pathway in some settings97.”
From The telomere syndromes (2012) · cites this paper as [96]
In the citing paper
“Importantly, removal of p53 function rescued many of the cellular defects despite the presence of critically short telomeres, including growth arrest in cell culture, testicular atrophy, intestinal and germ cell apoptosis46.”
From Telomere dysfunction and tumour suppression: the senescence connection (2008) · cites this paper as [46]
Citations
Cites
The serial cultivation of human diploid cell strains
Hayflick, L., & Moorhead, P. S. (1961) · Experimental Cell Research · doi:10.1016/0014-4827(61)90192-6 · Cited by 8,508
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“INK4a2/2 centration of 10 mM for 3.5 hr. Cells were processed as previouslymice lack functional p19ARF, a modulator of p53 function described (Serrano et al., 1997).activated by inappropiate oncogene activation, but re- tain intact DNA damage–induced p53 activation (Kamijo MEF Transformation…”
MethodInfluentialExtension of Life-Span by Introduction of Telomerase into Normal Human Cells
Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C.-P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., & Wright, W. E. (1998) · Science · doi:10.1126/science.279.5349.349 · Cited by 4,975
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,911
Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
Land, H., Parada, L. F., & Weinberg, R. A. (1983) · Nature · doi:10.1038/304596a0 · Cited by 2,804
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA
Blasco, M. A., Lee, H.-W., Hande, M. P., Samper, E., Lansdorp, P. M., DePinho, R. A., & Greider, C. W. (1997) · Cell · doi:10.1016/s0092-8674(01)80006-4 · Cited by 2,108
Self-citation
Cited by
Sorted by citations
Items 601–700 of 975
Age-by-disease biological interactions: implications for late-life depression
McKinney, B. C., Oh, H., & Sibille, E. L. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00237 · Cited by 20
“Indeed, in peripheral tissues, it has been consistently demonstrated that telomeres become shorter as one ages and once telomeres reach a critical length, irreversible arrest of cell division or apoptosis is triggered (Hayflick and Moorhead, 1961; Chin et al., 1999; Sharpless and DePinho, 2004; Flores and Blasco, 2009…”
BackgroundZhang, Y., Shen, J., Lee, P., & Santella, R. M. (2007) · Cancer Investigation · doi:10.1080/07357900701561024 · Cited by 20
“The main function of telomeres is to cap chromosomal ends, thus preventing chromosomal fusions, chromosomal instability (CIS) and the activation of DNA-damage responses (30, 31).”
Linkage between mitochondrial genome alterations, telomere length and aging population
Zole, E., Zadinane, K., Pliss, L., & Ranka, R. (2017) · Mitochondrial DNA Part A · doi:10.1080/24701394.2017.1303490 · Cited by 20
Immortalized cells as experimental models to study cancer
Boehm, J. S., & Hahn, W. C. (2004) · Cytotechnology · doi:10.1007/s10616-004-5125-1 · Cited by 22
The in vitro life-span of human periodontal ligament fibroblasts
Sawa, Y., Phillips, A., Hollard, J., Yoshida, S., & Braithwaite, M. W. (2000) · Tissue and Cell · doi:10.1054/tice.2000.0100 · Cited by 20
Telomere status in chronic lymphocytic leukemia with TP53 disruption
Guièze, R., Pagès, M., Véronèse, L., Combes, P., Lemal, R., Gay‐Bellile, M., Chauvet, M., Callanan, M. B., Kwiatkowski, F., Pereira, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10927 · Cited by 23
Golubovsky, M. D., Weisman, N. Y., Arbeev, K. G., Ukraintseva, S. V., & YASHIN, A. I. (2006) · Experimental Gerontology · doi:10.1016/j.exger.2006.06.035 · Cited by 20
Telomeres, p21 and the cancer-aging hypothesis
Bell, J. F., & Sharpless, N. E. (2006) · Nature Genetics · doi:10.1038/ng0107-11 · Cited by 20
Stem cell ageing: does it happen and can we intervene?
Bellantuono, I., & Keith, W. N. (2007) · Expert Reviews in Molecular Medicine · doi:10.1017/s146239940700049x · Cited by 21
“39 Chin, L. et al. (1999) 53 deficiency rescues the adverse effects of telomere loss and cooperates”
BackgroundMaking the most of a little: dosage effects in eukaryotic telomere length maintenance
Harrington, L. A. (2005) · Chromosome Research · doi:10.1007/s10577-005-0994-5 · Cited by 20
“On the other hand, older p53-deficient animals show a wider spectrum of tumours when derived from a background with very short telomeres (i.e. later mTercj/j generations) (Chin et al. 1999, Artandi et al. 2000, Wong et al. 2000, Artandi & DePinho 2000, Farazi et al. 2003).”
Complex roles for telomeres and telomerase in breast carcinogenesis
Artandi, S. E. (2002) · Breast Cancer Research · doi:10.1186/bcr553 · Cited by 20
Self-citationThe telomere-mitochondrial axis of aging in newborns
Stukken, C. V. D., Nawrot, T. S., Alfano, R., Wang, C., Langie, S. A. S., Plusquin, M., Janssen, B. G., & Martens, D. S. (2022) · Aging · doi:10.18632/aging.203897 · Cited by 22
“How can our observations be explained based on the proposed hypothesis (Figure 1)? DNA damage and excessive telomere shortening caused by intracellular stresses or environmental signals activate p53 [12, 24], which has commonly been referred to as the ‘guardian of the genome’ due to its role in protecting the cell fro…”
Chromosomal instability: a key driver in glioma pathogenesis and progression
Mazzoleni, A., Awuah, W. A., Sanker, V., Bharadwaj, H. R., Aderinto, N., Tan, J. K., Huang, H. Y. R., Poornaselvan, J., Shah, M. H., Atallah, O., et al. (2024) · European journal of medical research · doi:10.1186/s40001-024-02043-8 · Cited by 21
“In cells with critical telomere dysfunction, dicentric chromosome formation, and genomic instability, there is an increased vulnerability to oncogenic transformation [41–43].”
BackgroundConquering the complexity of p53
Attardi, L. D., & DePinho, R. A. (2003) · Nature Genetics · doi:10.1038/ng0104-7 · Cited by 19
Self-citationBiology of telomeres: importance in etiology of esophageal cancer and as therapeutic target
Pal, J., Gold, J. S., Munshi, N. C., & Shammas, M. A. (2013) · Translational research · doi:10.1016/j.trsl.2013.09.003 · Cited by 19
“Data from other laboratories also indicate that severe telomere shortening or telomere dysfunction contributes to the development of cancer (49, 51, 52).”
IL-7Rα deficiency in p53null mice exacerbates thymocyte telomere erosion and lymphomagenesis
Kibe, R., Zhang, S., Guo, D., Marrero, L., Tsien, F., Rodrı́guez, P. C., Khan, S., Zieske, A. W., Huang, J., Li, W., et al. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2011.203 · Cited by 19
“Chromosome translocations and fusions can be triggered by various mechanisms, such as T-cell receptor rearrangement, DNA damage-induced double-strand DNA breaks, telomere dysfunction, and DNA repair defects.(10,18,20,22,23) Robertsonian translocations frequently occur in cells incurring telomere dysfunction.”
BackgroundCytokine production by bone marrow mononuclear cells in inherited bone marrow failure syndromes
Matsui, K., Giri, N., Alter, B. P., & Pinto, L. A. (2013) · British Journal of Haematology · doi:10.1111/bjh.12475 · Cited by 19
“These IBMFS have been reported to show dysregulation of p53 (Chin et al, 1999; Elghetany & Alter, 2002; Zhang & Lu, 2009; Bellodi et al, 2010; Narla & Ebert, 2010; Ceccaldi et al, 2012).”
Babizhayev, M. A., & Yegorov, Y. E. (2015) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.35515 · Cited by 20
p19Arf is required for the cellular response to chronic DNA damage
Bieging-Rolett, K. T., Johnson, T. M., Brady, C. A., Beaudry, V. G., Pathak, N., Han, S., & Attardi, L. D. (2016) · Oncogene · doi:10.1038/onc.2015.490 · Cited by 19
“…is not due to a single, acute genotoxic insult but rather continual, low-level genomic damage caused by unscheduled DNA replication and consequent replication fork collapse, telomere attrition, and increased ROS levels resulting from enhanced metabolic activity or hypoxia/ reperfusion 6, 19-24 .”
Birth and death: Evidence for the same biologic clock
Phillippe, M., & Phillippe, S. (2017) · American Journal of Reproductive Immunology · doi:10.1111/aji.12638 · Cited by 18
Xin, X., Senthilkumar, P. K., Schnoor, J. L., & Ludewig, G. (2015) · Environmental Science and Pollution Research · doi:10.1007/s11356-015-5187-y · Cited by 20
“Studies using knockout mice have demonstrated that the role of telomeres in cancer can both be limiting to tumor growth and promote tumorigenesis, depending on the cell type and genomic context (Chin et al. 1999; Greenberg et al. 1999).”
BackgroundSquamous cell carcinomas of the esophagus arise from a telomere-shortened epithelial field
Kammori, M., Poon, S. S. S., Nakamura, K., Izumiyama, N., Ishikawa, N., Kobayashi, M., Naomoto, Y., & Takubo, K. (2007) · International Journal of Molecular Medicine · doi:10.3892/ijmm.20.6.793 · Cited by 19
Signaling on telomerase: a master switch in cell aging and immortalization
Li, H., & Liu, J. (2002) · Biogerontology · doi:10.1023/a:1015232102470 · Cited by 19
de Grey, A. D. N. J., Campbell, F. C., Dokal, I. S., Fairbairn, L., Graham, G. J., Jahoda, C. A. B., & PORTERG, A. C. G. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1297.026 · Cited by 19
“Interestingly, mice lacking p53 as well as telomerase show a delay in the major phenotype that can be measured at an early enough age not to be masked by the cancers that result from lack of p53, namely sterility: TERC p53 mice can be bred for two generations longer than the simple TERC knockouts.(67)”
Expression of Telomeric Repeat Binding Factor-1 in Astroglial Brain Tumors
Torre, D. L., DIVITIIS, O. D., Conti, A., Angileri, F. F., Cardali, S. M., Aguennouz, M., Aragona, M., Panetta, S., D’Avella, D., Vita, G., et al. (2005) · Neurosurgery · doi:10.1227/01.neu.0000156468.41461.6f · Cited by 20
“In human somatic cells, telomeres shorten with successive cell divisions, resulting in progressive genomic instability, altered gene expression, and cell death (42) via p53-dependent or -independent mechanisms (10, 51).”
Telomerase: Not Just Black and White, but Shades of Gray
Liu, J. (2000) · Molecular Cell Biology Research Communications · doi:10.1006/mcbr.2000.0203 · Cited by 18
Boosting NAD ameliorates hematopoietic impairment linked to short telomeres in vivo
Stock, A. J., Ayyar, S., Kashyap, A., Wang, Y., Yanai, H., Starost, M. F., Tanaka-Yano, M., Bodogai, M., Sun, C., Wang, Y., et al. (2023) · GeroScience · doi:10.1007/s11357-023-00752-2 · Cited by 25
“Mice deficient in Terc or Tert exhibit gradual telomere loss with successive generations (G), and at late generations (≥ G3), harbor critically short telomeres that elicit a DNA damage response and contribute to the loss of cell viability and genome stability [15–21].”
Backgroundp53 regulates diverse tissue-specific outcomes to endogenous DNA damage in mice
Hill, R. J., Bona, N., Smink, J., Webb, H. K., Crisp, A., Garaycoechea, J. I., & Crossan, G. P. (2024) · Nature Communications · doi:10.1038/s41467-024-46844-1 · Cited by 21
Role of Telomere Dysfunction in Genetic Intratumor Diversity
Genescà, A., Pampalona, J., Frías-López, C., Domínguez, D., & Tusell, L. (2011) · Advances in cancer research · doi:10.1016/b978-0-12-387688-1.00002-8 · Cited by 19
PinX1: a sought-after major tumor suppressor at human chromosome 8p23
Zhou, X. Z. (2011) · Oncotarget · doi:10.18632/oncotarget.339 · Cited by 18
Telomerase as a novel and potentially selective target for cancer chemotherapy
Parkinson, E. K. (2003) · Annals of Medicine · doi:10.1080/07853890310006361 · Cited by 18
Bekaert, S., Derradji, H., Meyer, T. D., Michaux, A., Buset, J., Neefs, M., Mergeay, M., Jacquet, P., Oostveldt, P. V., & Baatout, S. (2005) · DNA repair · doi:10.1016/j.dnarep.2005.05.010 · Cited by 18
p53 and ageing: too much of a good thing?
Kirkwood, T. B. L. (2002) · BioEssays · doi:10.1002/bies.10111 · Cited by 19
Elmore, L. W., Turner, K. C., Gollahon, L., Landon, M. R., Jackson‐Cook, C. K., & Holt, S. E. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.1.4.13 · Cited by 18
Telomere Length, Telomere-binding Proteins, and DNA Damage SignalingPreprint
Hemann, M. T., Hackett, J. A., IJpma, A. S., & Greider, C. W. (2000) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2000.65.275 · Cited by 18
Self-citationcGAS-STING are responsible for premature aging of telomerase-deficient zebrafish
Şerifoğlu, N., Allavena, G., Lopes-Bastos, B., Marzullo, M., Marques, A., Colibert, P., Bousounis, P., Trompouki, E., & Ferreira, M. G. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00482-5 · Cited by 21
“Similar to late-generation telomerase-de fi cient mice (Rudolph et al, 1999), lack of p53 leads to organismal rescue and increased fertility, allowing for extra generations with ever-shorter telomere mice (Chin et al, 1999).”
Clonal inactivation of TERT impairs stem cell competition
Hasegawa, K., Zhao, Y., Garbuzov, A., Corces, M. R., Neuhöfer, P., Gillespie, V. M., Cheung, P., Belk, J. A., Huang, Y., Wei, Y., et al. (2024) · Nature · doi:10.1038/s41586-024-07700-w · Cited by 20
“Critical telomere shortening in mouse and human cells triggers a DNA damage response and the activation of the p53 tumour suppressor protein, inducing either cell death or senescence 33 .”
Self-citationG-Quadruplex structure: a target for anticancer therapy and a probe for detection of potassium
Chen, B., Liang, J., Tian, X., & Liu, X. (2008) · Biochemistry (Moscow) · doi:10.1134/s0006297908080026 · Cited by 17
Park, J.-E., Woo, S. R., Kang, C.-M., Juhn, K.-M., Ju, Y.-J., Shin, H.-J., Joo, H.-Y., Park, E. R., Park, I.-C., Hong, S. H., et al. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.12.018 · Cited by 17
XPF/ERCC4 and ERCC1: Their Products and Biological Roles
McDaniel, L. D., & Schultz, R. A. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-09599-8_8 · Cited by 17
Effectors of mammalian telomere dysfunction: a comparative transcriptome analysis using mouse models
Franco, S., Canela, A., Klatt, P., & Blasco, M. A. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi107 · Cited by 18
Altered States of Telomere Deprotection and the Two-Stage Mechanism of Replicative Aging
Zou, Y. S., Misri, S., Shay, J. W., Pandita, T. K., & Wright, W. E. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01569-08 · Cited by 17
Middleman, E. J., Choi, J., Venteicher, A. S., Cheung, P., & Artandi, S. E. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2146-2159.2006 · Cited by 17
“For metaphase analysis, cells treated with Colcemid and metaphase chromosomes were prepared on glass slides as previously described ( 16 ).”
Self-citationTelomeres and telomerase in adrenocortical tissue maintenance, carcinogenesis, and aging
Else, T. (2009) · Journal of Molecular Endocrinology · doi:10.1677/jme-08-0189 · Cited by 17
Mouse models to study the role of telomeres in cancer, aging and DNA repair
Blasco, M. A. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00450-1 · Cited by 16
Can a single model explain both breast cancer and prostate cancer?
Friedman, A. (2007) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-4-28 · Cited by 17
Bisht, S., Mao, Y., & Easwaran, H. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001020 · Cited by 18
Dynamics of telomeric chromatin at the crossroads of aging and cancer
Ye, J., Wu, Y., & Gilson, É. (2010) · Essays in Biochemistry · doi:10.1042/bse0480147 · Cited by 15
Ferrara‐Romeo, I., Martínez, P., & Blasco, M. A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204909 · Cited by 16
Argilla, D., Chin, K., Singh, M., Hodgson, J. G., Bosenberg, M., Ortíz-de-Solórzano, C., Lockett, S. J., DePinho, R. A., Gray, J. W., & Hanahan, D. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.032 · Cited by 16
Self-citationSun, Y., Zhang, L., Zhao, L., Wu, X., & Gu, J. H. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv133 · Cited by 16
Asaka, S., Davis, C., Lin, S., Wang, T., Heaphy, C. M., & Shih, I. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001283 · Cited by 15
Rybanská, I., Ishaq, O. F., Chou, J., Prakash, M., Bakhsheshian, J., Huso, D. L., & Franco, S. (2012) · Oncogene · doi:10.1038/onc.2012.199 · Cited by 16
Impairment of osteocalcin production in senescent periodontal ligament fibroblasts
Sawa, Y., Phillips, A., Hollard, J., Yoshida, S., & Braithwaite, M. W. (2000) · Tissue and Cell · doi:10.1054/tice.2000.0104 · Cited by 16
David, G., Dannenberg, J.-H., Simpson, N. E., Finnerty, P. M., Miao, L., Turner, G. M., Ding, Z., Carrasco, R. D., & DePinho, R. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209734 · Cited by 16
“Similarly, p53 deficiency allows the conversion of telomere-based crisis into procarcinogenic process in mice (Chin et al., 1999).”
BackgroundSelf-citationAviv, A., & Harley, C. B. (2001) · Current Hypertension Reports · doi:10.1007/s11906-001-0029-3 · Cited by 16
TERT-TP53 mutations: a novel biomarker pair for hepatocellular carcinoma recurrence and prognosis
Li, J., Bai, L., Xin, Z., Song, J., Chen, H., Song, X., & Zhou, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-87545-z · Cited by 17
Zheng, X., Wezel, F., Azoitei, A., Meessen, S., Wang, W., Najjar, G., Wang, X., Kraus, J. M., Kestler, H. A., John, A., et al. (2021) · Cancers · doi:10.3390/cancers13153774 · Cited by 14
Mechanisms of telomere maintenance and associated therapeutic vulnerabilities in malignant gliomas
Waitkus, M. S., Erman, E. N., Reitman, Z. J., & Ashley, D. M. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae016 · Cited by 15
Sande, C. M., Chen, S., Mitchell, D. V., Lin, P., Abraham, D. M., Cheng, J. M., Gebhard, T., Deolikar, R. J., Freeman, C. M., Zhou, M., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci181659 · Cited by 15
“The tumor-resistant phenotype of Atm –/– Terc –/– mice contrasts with the increased rate of epithelial tumors in tp53 -deficient Terc –/– mice compared with Terc –/– mice (66, 67).”
Pereboeva, L., Hubbard, M. G., Goldman, F. D., & Westin, E. R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148793 · Cited by 15
“Attenuating p53 through different mechanisms rescues some of the defects associated with short telomeres, further supporting the role of p53 in telomere-related pathologies[17, 44].”
BackgroundThe telomere gestational clock: increasing short telomeres at term in the mouse
Phillippe, M., Sawyer, M. R., & Edelson, P. K. (2019) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2019.01.218 · Cited by 15
Telomeric chromatin: Roles in aging, cancer and hereditary disease
McCord, R., & Broccoli, D. (2008) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2008.08.005 · Cited by 18
How carcinogens (or telomere dysfunction) induce genetic instability: associated‐selection model
Blagosklonny, M. V. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02894-0 · Cited by 15
Links between telomere dysfunction and hallmarks of aging
Li, S., Liu, Z., Zhang, J., & Li, L. (2023) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2023.503617 · Cited by 15
Telomere dysfunction and cell cycle checkpoints in hematopoietic stem cell aging
Ju, Z., Zhang, J., Gao, Y., & Cheng, T. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0882-z · Cited by 14
“Deletion of p53 rescued the apoptosis in the testis of telomere dysfunctional mice, but the double knockout mice died earlier because of tumors [ 109 ].”
BackgroundTelomerase activity and p53-dependent apoptosis in ovarian cancer cells
Akeshima, R., Kigawa, J., Takahashi, M., Oishi, T., Kanamori, Y., Itamochi, H., Shimada, M., Kamazawa, S., Sato, S., & Terakawa, N. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1812 · Cited by 14
Lin, Y., Chang, C., Wong, C., & Teng, S. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008224 · Cited by 15
Telomere uncapping at the crossroad between cell cycle arrest and carcinogenesis
Gobbini, E., Trovesi, C., Cassani, C., & Longhese, M. P. (2014) · Molecular & Cellular Oncology · doi:10.4161/mco.29901 · Cited by 15
Walking the Telomere Plank Into Cancer
Wong, K., & DePinho, R. A. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg028 · Cited by 13
Self-citationThe Yin-Yang of DNA Damage Response: Roles in Tumorigenesis and Cellular Senescence
Li, X., Xu, H., Chong-an, X., Lin, M., Song, X., Yi, F., Feng, Y., Coughlan, K. A., Cho, W., Kim, S. W., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14022431 · Cited by 18
Escoffier, E., Rezza, A., de Climens, A. R., Belleville, A., Gazzolo, L., Gilson, É., & Dodon, M. D. (2005) · Retrovirology · doi:10.1186/1742-4690-2-77 · Cited by 18
Telomerase Activity and the Risk of Lung Cancer
Jeon, H.-S., Choi, J. E., Jung, D. K., Choi, Y. Y., Kang, H. G., Lee, W.-K., Yoo, S. S., Lim, J.-O., & Park, J. Y. (2012) · Journal of Korean Medical Science · doi:10.3346/jkms.2012.27.2.141 · Cited by 13
Dekker, P., de Lange, M. J., Dirks, R. W., van Heemst, D., Tanke, H. J., Westendorp, R. G. J., & Maier, A. B. (2010) · The Journals of Gerontology Series A · doi:10.1093/gerona/glq159 · Cited by 13
“Furthermore, p53 plays a major role in RS induced by telomere erosion (11,12).”
BackgroundWu, X., Jia, S., Zhang, X., Si, X., Tang, W., & Luo, Y. (2012) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2012.07.002 · Cited by 13
Hepatocarcinoma in Viral and Metabolic Liver Disease
Rosenthal, P. J. (2008) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e318158799b · Cited by 13
Effects of p21 deletion in mouse models of premature aging
Benson, E. K., Zhao, B., Sassoon, D. A., Lee, S. W., & Aaronson, S. A. (2009) · Cell Cycle · doi:10.4161/cc.8.13.8997 · Cited by 14
Self-citationWen, V. W., Wu, K., Baksh, S., Hinshelwood, R. A., Lock, R. B., Clark, S. J., Moore, M. A. S., & MacKenzie, K. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0979 · Cited by 13
Vakili, S. A., George, A., Ayatollahi, S. A., Martorell, M., Ostrander, E. A., Salehi, B., Martins, N. A., & Sharifi‐Rad, J. (2020) · Cellular and Molecular Biology · doi:10.14715/cmb/2020.66.4.15 · Cited by 14
A mouse model of human oral-esophageal cancer
Opitz, O. G., Harada, H., Suliman, Y., Rhoades, B., Sharpless, N. E., Kent, R., Kopelovich, L., Nakagawa, H., & Rustgi, A. K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215324 · Cited by 13
Senescence and its bypass in the vascular endothelium
Deborah, A. F. (2005) · Frontiers in bioscience · doi:10.2741/1588 · Cited by 13
Tamura, Y., Tao, M., Miyano‐Kurosaki, N., Takai, K., & TAKAKU, H. (2000) · Antisense and Nucleic Acid Drug Development · doi:10.1089/oli.1.2000.10.87 · Cited by 13
“Therefore, the HeLa cells treated with antisense oligonucleotides could bypass the p53-dependent early crisis and continue cell division until the telomere was shortened to a critical length and progressive genomic instability was induced (Chin et al., 1999).”
Telomeres and Mitochondrial Function
Finkel, T. (2011) · Circulation Research · doi:10.1161/res.0b013e31821bc2d8 · Cited by 13
“Here, they took advantage of previous observations that in their mouse model, p53 was activated as a consequence of telomere attrition.(3) Furthermore, past studies had shown that animal models exhibiting constitutively activated p53 are often characterized by a phenotype consistent with accelerated aging.”
p53 in the Molecular Circuitry of Bone Marrow Failure Syndromes
Rakotopare, J., & Toledo, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914940 · Cited by 15
Shelterin dysfunction promotes CD4+ T cell senescence in Behçet’s disease
Shi, J., Zhang, M., Zhang, L., Yu, X., Sun, L., Liu, J., Zhao, Y., & Zheng, W. (2023) · Rheumatology · doi:10.1093/rheumatology/kead703 · Cited by 13
Hartwig, F. P., & Collares, T. V. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.03.003 · Cited by 11
Nelson, W. G., Carter, H. B., DeWeese, T. L., Antonarakis, E. S., & Eisenberger, M. A. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00084-9 · Cited by 13
Tsai, C.-W., CHANG, W.-S., Xu, J., Xu, Y., Huang, M., Pettaway, C. A., Bau, D., & Gu, J. H. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa070 · Cited by 12
Breaking the aging epigenetic barrier
Sikder, S., Arunkumar, G., Melters, D. P., & Dalal, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.943519 · Cited by 12
“another activator of senescence, is also p53 dependent (Chin et al., 1999).”
Bejarano, L., Louzame, J., Montero, J. J., Megı́as, D., Flores, J. M., & Blasco, M. A. (2019) · iScience · doi:10.1016/j.isci.2019.08.012 · Cited by 11
Polychronopoulou, S., & Koutroumba, P. (2004) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200406000-00003 · Cited by 13
Sawa, Y., Yamaoka, Y., Kuroshima, S., & Yoshida, S. (2004) · Cell and Tissue Research · doi:10.1007/s00441-003-0837-7 · Cited by 12
Genetic Instability, Oncogenes, and the p53 PathwayPreprint
Wahl, G. M., & Vafa, O. (2000) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2000.65.511 · Cited by 12
Rakotopare, J., Lejour, V., Duval, C. J., Eldawra, E., Escoffier, H., & Toledo, F. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.050376 · Cited by 15
“Indeed, defects in telomere maintenance, DNA repair or ribosome function would all lead to p53 activation (Ceccaldi et al., 2012; Chin et al., 1999; McGowan et al., 2008), and the subsequent DREAM-mediated gene repression might have similar downstream 2.”
Telomere Uncapping, Chromosomes, and Carcinomas
Batista, L. F. Z., & Artandi, S. E. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.05.006 · Cited by 11
Self-citationTelomerase inhibitors: a new option for chemotherapy
Chen, Z., & Corey, D. R. (2003) · Advances in cancer research · doi:10.1016/s0065-230x(03)87173-7 · Cited by 11
Regulators of Telomerase Activity
Mauro, L. J., & Foster, D. N. (2002) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.26.5.f238 · Cited by 11
Telomerase inhibitors: a new option for chemotherapy
Chen, Z. J., & Corey, D. R. (2003) · Advances in cancer research · doi:10.1016/s0065-230x(03)87294-9 · Cited by 11
Telomere Crisis Shapes Cancer EvolutionPreprint
Nassour, J., & Karlseder, J. (2025) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041688 · Cited by 16
Chromosome instability induced by a single defined sister chromatid fusion
Kagaya, K., Noma-Takayasu, N., Yamamoto, I., Tashiro, S., Ishikawa, F., & Hayashi, M. (2020) · Life Science Alliance · doi:10.26508/lsa.202000911 · Cited by 11
“The fate of chromosome fusion has also been analyzed during telomere crisis induced by replicative telomere shortening in p53-compromised cells and mice that lack functional telomerase (Shay et al, 1991; Counter et al, 1992; Blasco et al, 1997; Chin et al, 1999).”
Metadata
- Authors
- Chin, L., Artandi, S. E., Shen, Q., Tam, A., Lee, S.-L., Gottlieb, G. J., Greider, C. W., & DePinho, R. A.
- Affiliations
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Quest Diagnostics (United States) (US)
- Johns Hopkins University (US)
- Corresponding author
- DePinho, Ronald A
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 1999-05
- Volume
- 97
- Issue
- 4
- Pages
- 527-538
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2027779909
- Cited by
- 979
- References
- 44
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 18 · 2023: 21 · 2022: 15 · 2021: 22 · 2020: 15 · 2019: 26 · 2018: 24 · 2017: 23 · 2016: 32 · 2015: 34 · 2014: 23 · 2013: 40 · 2012: 51
- FWCI
- 36.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01hd028317-05, 5r01hd034880-04, 5k08ar002104-04)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (K08AR02104-01)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD34880, R01 HD28317)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- p53, telomere dysfunction, telomere shortening, telomerase deficiency, telomere crisis, carcinogenesis, genomic instability, tumor suppression, apoptosis, growth arrest, telomere length
- MeSH terms
- Animals, Male, Mice, Inbred C57BL, Neoplasms, Phenotype, Spermatozoa, Testis, Tumor Suppressor Protein p53, Telomere, Apoptosis, Telomerase, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
